To assess and validate LRRC15, EFNA3, TSPAN13, and CA12 in terms of the protein level, immunohistochemistry (IHC) was performed on TMA slides containing 100 cases of invasive breast carcinomas, nine adjacent non-tumor breast tissue samples, and one adjacent breast tumor tissue sample, along with clinicopathological features. This evidence concerns the gene TSPAN13 and invasive breast carcinoma.